GENF — Genflow Biosciences Income Statement
0.000.00%
- £7.87m
- £7.18m
Annual income statement for Genflow Biosciences, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 0.142 | 0.988 | 1.33 | 1.63 |
Operating Profit | -0.142 | -0.988 | -1.33 | -1.63 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -0.142 | -0.988 | -1.34 | -1.63 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.142 | -0.988 | -1.34 | -1.63 |
Net Income Before Extraordinary Items | ||||
Net Income | -0.142 | -0.988 | -1.34 | -1.63 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.142 | -0.988 | -1.34 | -1.63 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0 | -0.006 | -0.005 | -0.006 |